QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.121566v1 322/3/1144    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Esposito, G. Articles by Steardo, L. Search for Related Content PubMed PubMed Citation Articles by Esposito, G. Articles by Steardo, L.

NEUROPHARMACOLOGY

Opposing Control of Cannabinoid Receptor Stimulation on Amyloid--Induced Reactive Gliosis: In Vitro and in Vivo Evidence

Department of Human Physiology and Pharmacology, University of Rome "La Sapienza", Rome, Italy (G.E., C.Sa., C.Sc. L.S.); Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy (T.I., D.D.F.); Department of Public Medicine, Second University of Naples, Naples, Italy (M.P.); and Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli (Naples), Italy (V.D.M.)

Beside cytotoxic mechanisms impacting on neurons, amyloid (A)-induced astroglial activation is operative in Alzheimer's disease brain, suggesting that persistent inflammatory response may have a role in the illness and that positive results may be achieved by curbing the astroglial reaction. Because the role of the endocannabinoid system could represent a promising field of research, the present study conducted in vitro and in vivo experiments to assess this system. C6 rat astroglioma cells were challenged with 1 µg/ml A 1-42 in the presence or absence of selective agonists and antagonists of cannabinoid (CB)1 and CB2 receptors. Furthermore, rats were inoculated into the frontal cortex with 30 ng of A 1-42 and were i.p. administered with 5 mg/kg of the same substances. Immunohistochemical and biochemical findings revealed that selective agonism at CB1 and antagonism at CB2 receptors was able to blunt A-induced reactive astrogliosis with subsequent overexpression of glial fibrillary acidic protein and S100B protein. Moreover, A provoked down-regulation of CB1 receptors together with a reduction of anandamide concentration, whereas CB2 receptors were up-regulated and 2-arachidonoyl glycerol concentration was increased. Finally, to our knowledge, the current study is the first showing that interactions at cannabinoid receptors result in a dual regulation of A-induced reactive astrogliosis. The data support the assumption that compounds able to selectively block CB2 receptors may have therapeutic potential in controlling A-related pathology, due to their beneficial effects devoid of psychotropic consequences.

Address correspondence to: Dr. Luca Steardo, P. le Aldo Moro, 5-00185 Rome, Italy. E-mail: luca.steardo{at}uniroma1.it